Adams, Jessica

Donepezil and memantine for moderate-to-severe Alzheimer's disease

Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine

Dementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

Cited by 782

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., et al. (2018) · PLOS Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 193

Determining the minimum clinically important differences for outcomes in the DOMINO trial

Howard, R., Phillips, P., Johnson, T., O'Brien, J., Sheehan, B., Lindesay, J., Bentham, P., Burns, A., Ballard, C., Holmes, C., et al. (2011) · International Journal of Geriatric Psychiatry

Dementia and Cognitive Impairment ResearchStatistical Methods in Clinical Trials

Cited by 185

Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD

Dyer, A. H., Murphy, C., Lawlor, B., Kennelly, S. P., Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., et al. (2020) · Journal of the American Medical Directors Association

Dementia and Cognitive Impairment ResearchPharmaceutical Practices and Patient Outcomes

Cited by 39